After six years of public hearings and behind-the-scenes lobbying by academic, government and industry infectious disease experts worried about drug-resistant pathogens, Congress is on the verge of passing new incentives to develop anti-infective drugs.

The provisions of the Generating Antibiotic Incentives Now (GAIN) Act (H.R. 2182) are incorporated in draft legislation to reauthorize PDUFA produced by Republicans on the House Energy and Commerce Committee and bipartisan leadership of the Senate Health, Education, Labor and Pensions Committee (HELP).